Tweet

Research Into Benefits Of Prilactone®

Author: CEVA
Posted: Monday 22nd February, 2010. 00:00:00

A new publication into the benefits of spironolactone, the active ingredient in Prilactone® manufactured by CEVA Animal Health, has supported the use of the product as part of first-line therapy for the treatment of dogs with congestive heart failure caused by mitral heart disease.

The double-blind placebo-controlled study1 involved 212 dogs on either spironolactone or a placebo, in addition to conventional therapy including an ACE inhibitor and furosemide. It revealed that over a 15 month period 25.5% of dogs either died, were euthanased or severely worsened in the placebo group compared to 10.8% in the spironolactone group. This represents a 55% reduction in the risk of cardiac morbidity-mortality and a 69% reduction in the risk of cardiac-related death or euthanasia.

Further research2 has also revealed that aldosterone antagonists, such as spironolactone, help to prevent myocardial fibrosis, a pathogenic process involved in the progression of heart failure.

Information is available by calling Fraser Broadfoot MRCVS at CEVA Animal Health on 01494 781510.

This article has been viewed 3428 times.

 

Comments about this article